据 wsj jan 28,2009 报导.Astellas Pharma Inc. announced an unsolicited takeover offer for biotechnology company CV therapeutics inc. valued at $16 a share ,or nearly $1 billion.
又 wsj Mar 8 ,2009 ."small stock focus" on the deals front,a large-cap Gilead Sciences agreed to acquire Palo Alto,Calif biopharmaceutical company CV Therapeutics for $1.4 billion,helping CVto stave off a hostile takeover bid by Japan's Astellas Pharma.CV's shares closed up 5.04,or 32%,at 21.04.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment